Royal Canin has launched NATOM Explorer, an interactive online tool designed to help the entire practice team visualise and explain the cat and dog anatomy and disease conditions to their clients.
NATOM (‘aNATOMical map’) hosts a library that supports explanations given by the veterinary surgeon or nurse to the owner during or after the consultation. The tool acts as an interactive reference for vets and vet nurses, boasting a 360 degree navigation of the anatomy, three levels of zoom, full image annotation and the ability to print and share bespoke images and save them for future reference.
Users of the charts are able to study the skeletal, nervous, circulatory, muscular, visceral and more superficial layers of the anatomy. In addition, there are ‘special views’ of over 100 common disease processes which graphically describe illness presentation, clinical signs, diagnosis and treatment as well as giving pointers on long-term management.
Marianne Lomberg, Veterinary Marketing Manager at Royal Canin, said: "The tool was initially launched to vet students in early 2015 and, excitingly, following its highly successful introduction, we have now rolled it out to vet practices. NATOM Explorer™ is an easy to use, time-saving tool which can help explain all disease conditions in a simplified way, which is particularly key when presenting complex health topics and diseases to clients. We believe the tool will be highly beneficial to practices and look forward to seeing it going on to benefit owners and their pets across the country."
All information on NATOM can be personalised by the user by adding comments, sketches and uploading other files before saving and sharing the information. All the available content is written and verified by experts in anatomy and small animal practice, with significant contributions from Dr Alex German, Professor Tim Gruffydd-Jones and Dr. Kit Sturgess.
Practices interested in the tool can visit www.vetportal.royalcanin.co.uk for further information
The researchers say the effectiveness of cheaper devices could result in wider use amongst farmers, vets and hoof trimmers helping to identify lameness earlier.
The study, led by RVC undergraduate veterinary student, Aidan Coe, alongside Dr Nicola Blackie, a senior lecturer in Production Animal Science at the RVC, compared the thermal images of 83 cows’ hind feet, captured with both high and low cost thermal imaging devices.
Very little difference was identified in the performance and quality of the devices despite the low-cost device being 2% the cost of the high cost device.
Images captured suggested that low-cost thermal imaging devices would be the most cost-effective choice to aid in the identification of lameness.
This study highlights the effectiveness of cheaper infrared thermal imaging devices in identifying the condition which has the potential to lead to the wider use of the devices by farmers, vets and hoof trimmers, in turn allowing the condition to be identified earlier.
Whilst high-cost devices have sometimes been used to detect lameness in cattle, the price point of up to £20,000 and fragility has previously limited their usefulness in a farm setting.
Aidan Coe, Undergraduate Veterinary Student at the RVC, and lead researcher on this paper, said: “There is a possibility that low-cost infrared thermal imaging devices could be used as an objective, cost-effective method of assessing the lameness of the national herd, which may prove a useful adjunct to the current lameness detection methods.”
The full paper can be accessed at: https://www.mdpi.com/2306-7381/9/8/414
Reference
Vetoquinol UK has launched Dolpac®, its new wormer for dogs.
Dolpac® is a broad spectrum anthelmintic for dogs containing pyrantel, oxantel and praziquantel. Individually these ingredients are effective against individual worm species and the combination of all three provides specific activities against the most common roundworm and tapeworm species.
According to the company, clinical studies carried out in accordance with internationally recognised guidelines have shown that Dolpac® provides an excellent ability to reduce parasitic infection.
“Dolpac® offers vets and their clients an easy to use worming alternative at an affordable price,” explains Mark Leddy, Vetoquinol’s Marketing Department Manager. “Our aim is to help to increase the number of dog owners worming their pets at the correct frequency, which will not only protect their dogs, but their children as well. We have introduced a number of features to help achieve this objective, there are three tablet sizes to cover all weight ranges and the tablets are flavoured and easy to give, and there are dispensing envelopes in every pack. We also provide a dosing wall chart and a client worming guide.”
For more information, contact your Vetoquinol representative or visit the Dolpac website, http://www.dolpac.co.uk/, which offers information for both vets and clients.
CEVA Animal Health has launched the anti-inflammatory Meloxidyl for cattle and pigs.
Meloxidyl is meloxicam-based solution for the management of respiratory disease, mastitis and diarrhoea in cattle and non-infectious locomotor disorders and puerperal septicaemia and toxaemia in pigs. It is given via a single injection, when used in combination with suitable anti-infectives.
According to the company, Meloxidyl's one shot protocol means it is quick and economical to use; it allows control of inflammation and endotoxins and reduces somatic cell count, recovery time and risk of culling after clinical mastitis; it reduces the economical impact of respiratory signs in comparison with flunixin-based products and reduces the major clinical signs caused by toxins in cases of neonatal diarrhoea.
Meloxidyl can be used in combination with the company's range of anti-infectives, which includes Marbokem, Cevaxel and Florkem.
For further product information contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
Fort Dodge Animal Health has announced that its Zulvac 8 Ovis® Bluetongue sheep vaccine is now licensed and available in the UK. The company believes that the product will provide significant benefits to sheep farmers.
Zulvac 8 Ovis® is an inactivated adjuvanted vaccine for the active immunisation of sheep by subcutaneous injection against Bluetongue Serotype 8. It also provides a reduction in viraemia. Administration is a two x 2 ml dose primary course in year one but only a single shot booster in the second year.
The use of Zulvac 8 Ovis as a booster for animals previously vaccinated with a primary course from other manufacturers is in line with Defra (2009) guidance: 'No problems are anticipated with re-vaccinating animals which have already received a primary course of vaccination with a different vaccine 1'.
The first dose can be administered from one month of age and Zulvac 8 Ovis® is proven for use in pregnant sheep. The onset of immunity is provided 25 days after the second dose.
Fort Dodge says Zulvac provides cost savings to farmers through its pricing strategy. While the price for the two dose primary course is competitive with alternative vaccines, for animals which were vaccinated last year and require only a single shot booster, the cost will be half that of competitive offerings, providing a significant incentive to farmers to vaccinate.
The vaccine is supported by a specific Zulvac Ovis fixed 2ml dose applicator with Sterimatic needle protector and cleaning system which aids administration and hygiene and is sold separately.
David Bartram MRCVS, Veterinary Technical Manager at Fort Dodge, said: "Sheep farmers have been waiting for a Bluetongue vaccine which offers a cost effective solution to vaccination - particularly for animals which received their primary course last year and are simply in need of a booster. We expect the fact that it's licensed for use in pregnant sheep to also prove attractive.
"Zulvac 8 Ovis® is the latest addition to Fort Dodge's Zulvac range for both cows and sheep. It is already used in Europe and has helped protect millions of animals."
The BSAVA has announced that comic Michael McIntyre has joined the line up for Congress Party Night.
McIntyre will be joining comedian Fred MacAulay and ventriloquist Paul Zerdin
To register for BSAVA, click here.
Elanco Animal Health has announced the launch of Osurnia, a new treatment which it says will drive compliance when treating canine otitis externa infections.
According to the company, compliance with daily ear drops has been shown to be poor, with up to 80% of owners administering the incorrect dose to their pet. The most common reason for a lack of compliance is the difficultly in applying the drops1.
Elanco says that Osurnia has the potential to improve compliance in treating otitis externa significantly, because unlike other medications which require 5-28 doses during the course of treatment2, Osurnia only needs two-doses given a week apart.
Osurnia contains a gel formulation of three active ingredients including the antibiotic florfenicol, which is new to companion animal treatment in the UK, terbinafine, which inhibits the growth of yeast as demonstrated for Malassezia spp., and the glucocorticosteroid, betamethasone acetate, to help relieve discomfort.
Osurnia is administered in a pre-measured, single-dose tube designed to ensure the right dose every time. It has a flexible, soft tip designed to make treatment with Osurnia a comfortable experience for the dog. The gel formulation squeezes out of the tube and spreads through the ear, adhering inside the ear canal for long-lasting action. The dose is the same for any dog, regardless of size and weight.
Alice Laurens, DVM MRCVS, dermatology marketing manager at Elanco Animal Health said: “Otitis externa is a common challenge for both vets and clients, with ear infections among the ten most frequent reasons for dogs to be presented with vets, affecting up to 20% of dogs3.
“Osurnia is an innovative, effective treatment that is administered in just two doses ensuring it is much more convenient for pet owners thereby increasing the likelihood that they will complete the entire treatment schedule leading to more comfortable dogs and peace of mind for owners.”
Elanco has produced a client leaflet on treating otitis externa with Osurnia. For further information, or to order client leaflets, please contact your local Elanco Animal Health Territory Manager or email elancoCAH.uk@elanco.com.
References
A Lincolnshire couple desperate to find an alternative to Elizabethan veterinary collars, after their dog Tess suffered a traumatic experience, have invented a new range of wound coverings called Cozi-fit.
According to Terri and Dave Ward from Skellingthorpe near Lincoln, who designed the new product, Cozi-fit is the clear alternative to Elizabethan or Buster collars. It comes in five different sizes, and the couple say that Cozi-fit is already going down well with vets and pet owners alike.
The idea for the Cozi-fit came about after the Ward's dog Tess had a hysterectomy. Dave said: "The hysterectomy was stressful enough, but Tess then had to wear a collar to stop her licking the wound. We also had to isolate her from our other dogs and she quickly became depressed and stopped eating.
"We were so worried about her that I decided to try and make a replacement using a pillowcase which we attached to her collar and fastened round her torso and hindquarters. As the wound was covered she could be around our other dogs and her movement wasn't restricted in any way.
"I was so delighted with the result that I decided to refine my design and took it to our local vet to get his opinion and it kind of grew from there. The wound coverings now come in five different sizes to suit all dogs and cats and are made from durable cotton fabric.
"We now supply over 30 veterinary surgeries including a number of Companion Care vet surgeries as well as the RSPCA and are currently in negotiation with retailers up and down the country."
Peter Munro from Whitegates Veterinary Practice said he was impressed when Terri first came to him with her initial idea: "Cozi-fit wound covers have proved to be a great benefit in protecting abdominal and castration wounds from self-trauma, especially where collars are not well tolerated and we've had some really positive feedback from our clients."
Although the product has been well received since coming on the market Dave says there are still thousands of vets, breeders and pet owners who are unaware of Cozi-fit.
"Vets perform over three million operations every year in the UK, many of which will be neuters, caesarean sections or other types of abdominal surgery, and Cozi-fit is ideal for these types of procedures.
"It is easy to fit, allows free and natural movement at all times and is a more pleasant experience for both the animal and their owner."
For more information about Cozi-fit please visit http://www.cozi-fit.com/.
The small animal and business meeting takes place on the 2nd and 3rd October. The farm and business national meeting is on the 18th and 19th September, and the equine and business meeting is on the 9th and 10th October.
The small animal meeting will also cover other topics such as the art of conversations to dentistry, while the farm meeting will focus on team working, competitive advantage, genomics and mental resilience.
All three events include a team-based activity and a social evening which offers the chance to network and exchange experiences and ideas.
Susan Goodfellow, the Chief Marketing Officer at XLVets said: "It's fine to know what we do but to actually experience it as part of our community is quite different. We know that talking to members and being part of a group of individuals that come together to determine their own future is the best way for veterinary professionals to see what's possible and how we strive for excellence together."
XLVets is also encouraging anyone who is thinking about starting their own practice to attend the events; the company has a number of programmes designed to support prospective owners with things like finding funding, identifying the right financial set up, and acquiring the skills needed to lead a team effectively.
Susan says many vets have a strong entrepreneurial mindset but lack support or know-how to allow them to take the first step to ownership: "Locum roles and mobile set ups are often stepping stones to practice ownership but the barriers can seem significant, not to mention any personal reservations people might have about all it entails. Support from like-minded colleagues who can openly share their experiences can help to make it seem possible, desirable and achievable."
Veterinary professionals wishing to attend one of the meetings should contact Colm McGinn, Chief of Implementation, in confidence, at colm.mcginn@xlvets.co.uk or call 01228 711788.
The practice has been leading research into the devastating disease since 2012 and has collated information on all confirmed cases across the country.
The disease, which originally appeared in the late 1980s, was first detected in the UK in 2012.
When it affects the kidneys, it has a 90% mortality rate.
The new site offers advice and information, including a live map of confirmed cases across the UK, for both vets and pet owners.
David Walker, American, RCVS and EBVS European specialist in small animal internal medicine, leads the team at Anderson Moores and is the UK’s foremost authority on the disease.
He said: “We have been at the forefront of research into CRGV for almost a decade now and have witnessed first-hand the often-devastating effects of the disease.
“In launching this new website, we aim to inform pet owners and colleagues in the veterinary industry about CRGV.
“We hope the confirmed case map will prove useful.
"Although an environmental trigger has not been definitively proven, the seasonality of the disease makes it eminently possible and the map allows everyone to see the location of confirmed cases.”
So far this year, Anderson Moores has recorded a total of 26 confirmed cases of CRGV.
This number comes on the back of 47 confirmed cases during 2020, 19 cases in 2019 and 18 in 2018.
277 cases have been confirmed since the disease was first recognised in the UK in 2012.
David said: “As we enter the winter months, we want to advise dog owners around the country to remain calm but vigilant and seek advice from their local vets if their dog develops an unexplained skin lesion(s), especially on the leg.
“Unfortunately, we find ourselves in the time of year when cases are most commonly identified – 92% of dogs with the disease are seen between November and May.
"This is understandably a concern for dog owners; however, the disease remains rare.
“If a dog is suspected to be suffering from CRGV, the best chance of recovery probably lies with early and intensive management which may be best provided at a specialist facility.
“Treatment primarily revolves around intensive management of the acute kidney injury and is sadly only successful in around 10% cent of cases.”
Visit https://www.alabama-rot.co.uk .
Sue, an RCVS and European Specialist in Veterinary Dermatalogy and Senior Vice President of the European Society of Dermatology, says the failure to prioritise pain relief is having a "profound effect on the quality of life of both dogs and clients."
Sue is urging vets to think about the impact that pain has on both the dog and owner in cases of OE: "Otitis externa is painful, it’s debilitating, and the degree of discomfort is often underestimated by both the veterinary surgeon and by the client."
Sue also says vets should not underestimate the owner’s concern about pain in their dog. Owners recognise the clinical signs associated with the pain of OE and determine treatment success by their dog recovering from these distressing symptoms.
To help manage the pain associated with OE, Sue recommends a multi-modal approach: "In addition to systemic pain relief, which is really important, a potent topical steroid is really useful to reduce the inflammation inside that dog’s ear, and make it much more comfortable."
Sue also highlights OE treatments which are able to coat the ear canal and stay there long enough to treat the pathogens and provide sustained pain relief: "When you put it into the ear, Osurnia Gel coats the lining of the external ear canal which gives prolonged contact with the lining of the canal to help treat the pathogens inside that dog’s ear."
Elanco says that despite Osurnia entering the market two years ago, some vets are still saving it for difficult cases. Sue said: "Too many vets use this [Osurnia] as a second-line drug and it should be used as a first-line product on the first occasion the dog comes through the door."
To watch the full series of videos and to find out more from Sue Paterson on treating otitis externa in dogs, visit: www.Osurnia.co.uk
Surrey-based Sarah Taylor and Zoe Daley launched the website earlier this year with a range which includes the Medicat wrap to make it easier to medicate and examine cats, and the Slumberpet Recovery Coat for dogs and for cats, for maintaining temperature during anaesthetics.
In addition, they've got a range of funky scrub caps, plus ID tags for your scissors and stethoscopes, fob watches, scrub hats and pens.
Colivet® solution, one of CEVA Animal Health’s range of 3 soluble antimicrobials for pigs has been renamed Coliscour®.
Phil McGuire, CEVA’s business unit manager, explains the reasoning behind the name change: “We simply felt that the easiest way to avoid confusion between our product and a totally different non-prescription product of a similar name was to give ours a new name that also reflects its use, hence Coliscour®.”
Agrimin has announced the launch of a new range of boluses for sheep and cattle that use 'eroding technology' to deliver a sustained supply of three trace elements for up to 180 days:
According to Agrimin, each bolus is designed to provide the full daily requirement of cobalt and selenium and the largest available daily supply of iodine to both cattle and sheep. The boluses do not contain any copper, an element known to cause issues in certain parts of the country, in closely managed dairy cows or in continental sheep breeds.
Each bolus is made up of two parts, held together by a soluble wrapper. After administration, the wrapper dissolves and the two halves remain in the reticulum where they erode and dissolve. This process delivers a continuous and regular supply of nutrients to the animal.
Agrimin's Dr Jamie Bennison said that the new range has been extensively trialled in New Zealand and at Glasgow Veterinary School: "Trials have confirmed a sustained release profile which ensures that iodine, selenium and cobalt levels are maintained throughout the active life of the bolus. In farm trials this has translated into higher levels of the elements in blood samples and improved animal productivity."
Treatment is one bolus per animal (48g for sheep; 160g for cattle) administered with an Agrimin bolus gun. One bolus is sufficient to meet the animal's full daily requirement for 180 days.
For more information about the 24•7 Iodine•Selenium•Cobalt range of cattle and sheep boluses, please visit http://www.agrimin.com/ or call 01652 688046.
Although the disease is commonly diagnosed later in life, a 2022 study of 123 dogs found that 40% of those aged between one and four years old had radiographic osteoarthritis, of which about half had clinical signs and of those only 2 were being treated for pain1.
Another 2022 study found that 38% of dogs over the age of one had osteoarthritic pain, but only half of them were presented for lameness or stiffness2.
Geoffrey Guyot, Pain and Inflammation Franchise Lead at Boehringer Ingelheim Animal Health, said: “Clinical signs of early osteoarthritis can be subtle.
"Some young dogs may present with overt lameness, but many compensate for years and manage to continue to perform their daily activities.
"Common compensations include gait or posture changes to unload the painful joint, which often go unnoticed.”
Boehringer says the aim of its campaign is to shift the perception of osteoarthritis as an old dog disease, to one which could affect dogs of all ages.
Boehringer also wants the campaign to bridge the gap between vets and dog owners, making it easier for owners to spot the early signs and initiate conversations about the condition.
Geoffrey added: "We hope the Arthritis AWARE campaign will raise awareness of early OA among owners to create more opportunities for you to diagnose and treat dogs with arthritis and improve their outcome.
"We encourage vet practices to join us on the journey so we can help improve dogs’ wellbeing together.”
Vet practices can help spread the word by downloading the Arthritis AWARE campaign pack which includes a waiting room video, a poster, owner-facing leaflets, and social media assets.
www.metacam.co.uk/aware
The finance was raised via a private placement with Sun Life Investment Management.
The College says it chose to finance via the private placement market due to the supportive buy and hold nature of the investor base, the strong demand within it for high quality higher education credits and the negotiated nature of the market.
In the top three of the QS world university rankings and with a strong financial performance history, the RVC’s £45 million senior unsecured note offering generated significant investor interest both within the UK and North America; with the offer four times over-subscribed, the RVC was able to take advantage of highly competitive long-term interest rates.
The secured funding will allow capital developments on both of the College's campuses.
Professor Stuart Reid, the RVC Principal, said: "I am absolutely delighted that we have secured this innovative blue chip financial backing in a deal which reflects our international reputation and leadership in the veterinary and biomedical sciences. We now look forward to investing in the next phase of capital development at the RVC, securing our position for years to come."
Candace Shaw, Head of Private Fixed Income, Sun Life Investment Management, said: "We are pleased to support the continued growth of the RVC, a specialised higher education institution with a renowned reputation both in the UK and internationally. The financing of the RVC represents a sound investment and aligns to Sun Life’s long-term investment objectives in this sector."
The webinars, which are free of charge, are:
The webinars join 'The gastrointestinal microbiome and its effects', which is already available for free viewing via The Webinar Vet.
Product Manager Kai Crawshaw said: “We’ve received excellent feedback on the webinars from those who have already viewed them through our Learning Alliance platform. We hope that by also making them available via The Webinar Vet, we will make them more easily accessible to a higher number of veterinary professionals keen to refresh their knowledge in these important areas.”
The Animalcare webinars can be viewed here: https://www.thewebinarvet.com/webinars/animalcare
The BSAVA reports that its Certificates in Medicine and Surgery have sold out in less than 5 minutes, beating the previous record of 20 minutes in their first year.
The Association says that whilst this is testament to the success and demand for its CPD, it is determined to find a way to avoid disappointing so many aspiring students - and after emergency talks over the weekend has decided to run a second intake of 30 students for each of the two programmes from January.
Dr Frances Barr, BSAVA's Academic Director, said: "Whilst we had only envisioned taking 30 new students onto each course this year, it quickly became clear that there is such a great appetite for this kind of accredited CPD in the profession right now. What a shame it would have been not to find a way to allow those ambitions to be fulfilled. So we are effectively going to run each programme twice in one year."
Quality control and sufficient student support is being met thanks to an overwhelming response from our teaching faculty and mentors. Dr Barr added: "BSAVA owes thanks to all those who lecture and work alongside our Certificate students. Without them we would not have been able to respond so quickly to this unprecedented demand".
The second programme will take place at two sites; BSAVA HQ in Gloucester, and the College of Animal Welfare in Huntingdon. Anyone who has not been able to take a place in the 2013 cohort will be offered priority registration for the 2014 in-take. For more information about BSAVA Certificates visit www.bsava.com or email administration@bsava.com.
The new site, which is ten minutes up the road from Southfield's current location in Basildon, Essex, is due to be ready in time for them to move in at the start of 2022.
When it opens, the centre will continue to offer 15 specialist-led services, but the team is projected to double in size as more specialists, clinicians and staff are recruited over the course of this year
The new premises has been made possible thanks to a big investment by parent company Linnaeus, backed by Mars Veterinary Health.
Southfields managing director Tim Richardson said: "The new hospital is a real statement of intent, a clear signal we are committed to delivering a level of excellence in treatment and care second to none.
"It will provide the region with one of the largest and best-equipped veterinary centres in, not only the UK, but also throughout Europe, with an extensive range of expertise in a wide variety of disciplines all under one roof.
"The fabulous facilities include a cutting-edge imaging suite, comprehensive treatment facilities and a new linear accelerator to assist our illustrious oncology team, which has already seen its status as one of the most experienced in the industry enhanced by the arrival of James Elliott, a renowned specialist in oncology.
"There will be seven operating theatres, 16 consultation rooms, recovery suites, lecture halls, a dedicated ICU department and there are plans for a future hydrotherapy suite.
Southfields says it also aims to lead the industry in terms of staff wellbeing, with yoga and boxercise classes among the activities available to the Southfields team.
Daniel Hogan, Southfields’ hospital director, said: “This is a huge move for us in every way. The increased size of the hospital will enable us to provide a dedicated staff wellbeing area and to offer a range of activities which will benefit our team in both body and mind.
“Along with exercise and relaxation classes, we will have an education centre which will offer some really exciting qualifications and courses for the wider profession.”
Bart Johnson, chief executive of Linnaeus, said: "This move is a reflection of the ambition of Southfields, Linnaeus and Mars to continue providing the best veterinary care in the UK."
For more information about Southfields’ new site, visit https://southfields.co.uk/veterinary-professionals/new-hospital/.
Ficoxil contains the active ingredient firocoxib, an NSAID from the coxib class, known for its analgesic, anti-inflammatory, and antipyretic properties.
Ficoxil is available in two strengths, 57 mg and 227 mg in packs of 30.
The tablets, which are presented in presented in a divisible and blister-perforated form, are hypoallergenic, gluten-free, and come in a beef flavour of animal-free origin.
Ficoxil is available now from all major veterinary wholesalers.
https://www.fortehealthcare.com/product/ficoxil
During the 60 days before to 30 days after calving, dairy cows experience a dip in their natural immunity, leaving them especially vulnerable to important diseases such as mastitis2, metritis3 and retained placenta.4 With serious cost consequences and implications for cow welfare and productivity, this makes the transition period one of the most challenging yet vital periods for vets to manage with dairy clients.
Imrestor (pegbovigrastim injection) is a pegylated form of the naturally occurring protein cytokine, bovine Granulocyte Colony Stimulating Factor (bG-CSF). Elanco says it helps restore the cow’s natural defences by increasing the number and restoring the function of neutrophils, the primary type of white blood cell that recognizes and kills harmful bacteria.
Fiona Anderson, Technical Vet at Elanco, said: "It’s no secret that a successful transition period is vital for maximising productivity in the next lactation, yet we are still ‘firefighting’ common transition diseases like mastitis rather than focusing on their true cause."
"Vets are under increasing pressure to adopt a more proactive approach, not least to reduce the use of antibiotics in livestock but with few credible alternatives. This can be challenging in dairy herds, particularly around calving when cows are susceptible to multiple disease challenges while their defences are low. Imrestor helps to restore a cow’s own natural immunity and strengthen her ability to defend against infection by a range of mastitis pathogens – thus helping to protect the cow against mastitis when she needs it most."
Available in pre-filled, single-dose syringes, Imrestor is administered with two injections – one seven days prior to the anticipated date of calving and the other within 24 hours after calving – with neither injection requiring a withdrawal period.
Kingsley Baxendale, Ruminant Marketing Manager at Elanco Animal Health said: "It can be extremely frustrating for vets to see their dairy farmers struggling with the stress and hassle of dealing with increased numbers of sick cows during calving; they have enough to deal with at the moment. We’re delighted that Imrestor can provide vets with a tool to help decrease the negative consequences associated with immune-related diseases like mastitis and maximise their herds’ lactation potential."
As part of the launch of Imrestor, Elanco also announced its new 'Pledge To Protect' initiative to encourage vets and farmers to make a pledge symbolising their commitment to address immune suppression in their dairy cows.
The number of pledges will be tracked using a life-sized 2D cow model, pictured above. For each pledge, which can be made online or at events, Elanco will make a £5 donation to The Royal Agricultural Benevolent Institution (R.A.B.I), which supports farmers in difficulty. As a thank you for showing support, all pledgers will automatically be entered into a weekly prize draw.
To find out more about using Imrestor and how you can make your pledge, visit www.vital90days.co.uk.
Ceva says CLAS vials are proven to be easy to use, practical and eco-friendly and are preferred by 99% of farmers on farm1. They have 33% less impact on the environment from cradle to grave than glass2 and are robust and shock resistant3 for fewer breakages and losses. They are made from a lightweight material to make the vials easier to be transported and handled4 and have an ergonomic ‘grip groove’ for easier handing5.
Peter Keyte, ruminant business unit manager at Ceva Animal Health said: "Ceva’s CLAS vials are hugely popular with both vets and farmers due to their practicality, ease of use and environmental credentials.
“We are therefore delighted that Ketofen has joined the extensive range of livestock injectables available in CLAS.”
For further information contact your local Ceva territory manager, call Ceva on 01494 781510 or email cevauk@ceva.com.
New legislation will be introduced in the New Year making slaughterhouse CCTV a legal requirement in all areas where live animals are present, with unrestricted access to at least 90 days of footage for Official Veterinarians. The new law will come into force in the spring, with slaughterhouses allowed an adjustment period of up to six months.
The new legislation followed a public consultation which was overwhelmingly in favour of compulsory CCTV. Defra says that out of almost 4,000 respondents, more than 99% were supportive of the plans.
Environment Secretary Michael Gove said: "We have some of the highest animal welfare standards in the world and want to cement our status as a global leader by continuing to raise the bar.
"The reaction to this consultation highlights the strength of feeling among the public that all animals should be treated with the utmost respect at all stages of life and be subject to the highest possible welfare standards.
"These strong measures also provide a further demonstration to consumers around the world that as we leave the EU we continue to produce our food to the very highest standards."
BVA Senior Vice President Gudrun Ravetz said: "The mandatory installation of CCTV is a vital tool to ensure high standards of animal health, welfare and food safety in all slaughterhouses.
Official Veterinarians carry out an essential role in slaughterhouses by independently assessing and reporting breaches of animal welfare, and unrestricted access to CCTV footage will allow them to carry out this role even more effectively.
We have been campaigning for these measures for a number of years and it is reassuring to see such a high level of support for their implementation from industry and the public."
Heather Hancock, Chairman of the Food Standards Agency, said: "The Secretary of State’s decision to require CCTV in all slaughterhouses is a welcome step towards ensuring that animal welfare and hygiene standards are met across the meat industry.
"Last year, the FSA Board concluded that, without mandatory CCTV in slaughterhouses, we would see minimal further progress in businesses improving animal welfare or complying with official controls to protect public health.
"We look forward to working with the industry as CCTV plans are implemented, and to seeing public confidence rise as a result."
The government will now further discuss the details of bringing in the proposals and present draft legislation to Parliament as soon as Parliamentary time allows.
Photo: Lititz, Pennsylvania. Hoisting a slaughtered steer in Benjamin Lutz's slaughterhouse, 1942. Wikipedia.
Virbac Animal Health has announced that registrations on BackHome BioTec, the company's microchip identification service, were moved to the Petlog Database with effect from Monday 12 September 2011.
Virbac says it moved to the UK's largest independent microchip registration database in order to offer an enhanced level of service and support, both to veterinary staff and pet owners.
Practices using the BackHome BioTec system are being asked to log onto www.virbacbackhome.co.uk to create a new account.
Gillian Brown, Product Manager for BackHome at Virbac, said: "BackHome has established itself as a popular, cost-effective and easy to use microchipping system. We believe that in appointing Petlog to manage our registrations we will now be offering a 'best of breed' service for veterinary staff and pet owners.
"We're extremely grateful to Celia Walsom, Petlog Executive, and her team. They have demonstrated unfailing energy, expertise and total dedication to ensuring this move has run smoothly and effectively for all our customers. I am confident that they will benefit from Petlog's commitment to provide a comprehensive identification service which is easy, convenient and secure to use.
"All our existing customers need to do is go to the new website (www.virbacbackhome.co.uk/) and set up an account - it's a simple and quick process. We'll also be providing a range of promotional materials to help them communicate the change to their own clients."
Petlog is owned and managed by the Kennel Club. Virbac says it is fully data compliant and defers income to ensure it can honour its lifetime promise to pet owners. Its Lost and Found helpline is available 24/7, 365 days a year and it is also a founder member of the European Pet Network.
Further information on BackHome BioTec is available on the new website, which also contains a direct link to Petlog.
For further information about BackHome BioTec, please contact your Virbac Territory Manager or call the company on 01359 243243.
Invicta Animal Health has launched SynVet-50, a licensed synthetic Sodium Hyaluronate (HA), for intra-articular treatment of lameness caused by joint dysfunction associated with non-infectious synovitis in horses.
The product is Invicta's first licensed medicine.
According to the company, the functional mechanisms of HA are directly dependent on the molecular weight and concentration of HA. 1 Therefore, SynVet-50 has been formulated with a molecular weight of 1.5m Daltons which is the highest of any synthetic HA available in the UK.
Invicta says that at 20mg per ml, SynVet-50 is also the most concentrated HA available.
Storage is at ambient temperature.
SynVet-50 is a 2.5ml solution containing 50mg HA, conveniently presented in a 5ml glass syringe.
Rob Watkins, Managing Director of Invicta said: "We are excited to be launching our first licensed medicine in the UK. The management team of Invicta have over 10 years experience in this market which has allowed us to provide a product strongly focussed on the clinicians needs, not just in terms of technical ability, but also in convenience of presentation".
For further information see www.invictavet.com or phone 01403 791313